Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The worst is over for the PPS. I believe the stock price is completely washed out..meaning once positive news flows it will move up nicely. Stay faithful...and patience is a virtue.
Happy Thanksgiving!!!
You must sit on the BOD or management team to know this. LMFAO!!
Nobody knows the future...but what I do know is they hired an extremely talented management and Board of Directors team...and have their Science validated in many peer journals.
Where the stock price goes from here..is a fools guess.
The investment approach to investing in a good biotech company is simple...invest in the the Science and management....and be patient. If you really think technical analysis applies to this type of company..you must be kidding yourself (we are a news driven investment).
Also, if you notice which people gripe here...its the ones who expected to make a fortune overnight....the markets dont work that way...and even the market makers (or market itself) are savvy enough to recognize that reality too.
Lastly, the investment thesis for AMBS is stronger now than the history of the company...we just need to the general markets to heal...and the risk on trade will come back slowly (which is why AMBS has turned and is slowly creeping back up as the markets strengthen).
Reality check 101:
The stock price has fallen as the Small caps have corrected well over 10% and many are down near 20%. Its called a Risk Off haircut (Wall street dumps high beta stocks and stays invested in high liquidity ..big cap oriented stocks as a defensive measure).
So please dont take any credit for the falling stock price here with AMBS; just look around at all the other small cap biotech stocks that have fallen in similar fashion ....you and Jbo think alike...just wanting to stroke your own egos and believe what you think........
"Just sayin" :)
I hear ya...its very obvious that many fear great and imminent success with AMBS. Usually, its an excellent sign when bashers are out in full force....I expecting major success (just requires continued patience and faith that management will execute...so much talent on board and leading the ship with this company).
Interesting! You invest alot of your time and energy covering this company so closely...yet you say its so dysfunctional. Really strange? Huh? Whats the hidden agenda?
Just curious...why would so many high profile backgrounds be willing to join an penny stock thats dysfunctional. A mirage perhaps?
Great post as usual JP....nobody here can try and attempt to distort these facts. Enjoy the low PPS ...because its not going to stay there much longer..the Small caps are ready to move higher in Q4 (nasty correction is over there)....and AMBS will get cranking once a few more positive PR's reconfirm LymPro data is strong ...and once MANF data is released as well.
I am so excited about the future...only wonder how some others will deal with their limited flexibility to flip as the PPS gets more more expensive. Sol and Jbo..what exactly will be your plans going forward....inquiring minds want to know?
LymPro update from Jason Napodono's recent blog. Dont let the manipulators here try to persuade you into selling your shares...here are the facts regarding the recently released LymPro data (a reality that some here conveniently leave out with when trying to convince everyone that LymPro doesnt work well):
JN blog info:
"We also believe that the data presented at AAIC and C4CT represents a “floor” in terms of LymPro accuracy. This is because the data presented at these events was from V1 and not designed for the multivariable analysis which Amarantus is moving forward on with V2. As the company fine-tunes the parameters of the test by tweaking things like cell lines and stimulations times, we believe the overall accuracy will trend higher. We are hoping to see the results from the LP-002 study in the next several weeks.
From a commercial product standpoint, it is not desirable to manipulate the test to increase one aspect of the analysis because overall accuracy is the balance of both Sensitivity and Specificity. But for enrollment in a clinical trial, when a big pharmaceutical company is clearly more interested in finding "True Positive" patients than worried about missing a "True Negative", fine tuning the analysis to enhance enrollment is a powerful tool under CLIA. Yet, Amarantus believes that even with 80% accuracy, LymPro offers meaningful utility for research only use (ROU) and clinical trial screening".
Already confirmed that Univariate data can only go higher from previously reported numbers. Minimally, it will be at least in the 80% range and possibly 90% +.
Where do you people come from exacty.....basically, you are calling GC a Liar. Its amazing how many here are lazy and make misleading statements constantly.
Two news releases coming next week. Expect solid data and an increasing PPS (LymPro Univariate data s/b solid) and Orphan eye data will be as well.
See you much higher...but keep dreaming. :)
Good management will be savvy enough to recognize when a drug technology is becoming obsolete and useless. And they will more than likely buy other compounds or develop new drug technologies (hint...Phenoguard)...which you have conveniently left out.
Facts are facts!! Please do your own due diligence and dont let the naysayers misguide you on their personal theories regarding AMBS. Outstanding management team, very promising drug technology in MANF, solid blood based test to detect Alzheimers (will be 1st to the market), a Drug discovery platform with Phenoguard and alliances with some top notch organizations and research institutions. Patience is a virtue....while some other people's opinions...are well...just that ...and opinion.
Objective analysis is a very good thing. GO AMBS!!!
On the record here that something big is brewing...either going to be acquired at a pre defined target price....or a serious partnership announcement looming. The PPS is being suppressed by whatever forces are involved...the more that it doesnt makes sense...it seems like classic WS manipulation at its finest.
The patient will be greatly rewarded...mark this post!!!!
Just a reminder: Message board posting is for entertainment purposes only. Also, please invest wisely and always do your own due diligence...whether the price is at $.06 or $.18 next week, a month from now or even one year down the road...who the fxxx cares.
A Financial re-engineering announcement can change everyone's perceptions in a heartbeat. The new division structure as of now (or is pending shortly is):
1)Drug development
2)Diagnostics
3)Phenoguard
Management could make a significant announcement in any of these three divisions and could split the current share structure out across all divisions and/or spin out a division as a special dividend to shareholders too. But more than likely; one of these divisions will be sold creating tremendous value (hopefully...before any Up listing occurs).
So many possibilities to speculate where this goes next.....and remember ....AUTHORIZED shares and ISSUED shares have no comparison whatsoever (well..maybe "Cash back Kaboom" even understand that reality). Moreover, until more shares are deemed issued; the dilution factor doesn't increase whatsoever.... no matter how many are authorized
Note: Unfortunately, it appears that some irresponsible investors and flippers here who have to deceive to misinform other investors (I believe in Karma in life...be careful to those who find it necessary to promote deception...somebody is watch you).
JP:
Too funny...its good to see the lighter side of life; even in many have a lot of dough riding here and take this investment very seriously. I think the MB is more for entertainment purposes at times. I dont post too often; but I do have significant respect for a few distinguished posters (sorry Michele...you are not one of them....can only imagine how anyone invests between $200-$400k ...but thinks just buying and holding is a guaranteed investment strategy with bonafide success).
There are so many moving parts with each turn; the strong will survive by making proper assessments on managements decisions; and I have seen make good companies fizzle because they took the wrong turns due to bad decision making, they didnt hire the right people, the technology was replaced by a competitor, the government implemented new laws that changed the market dynamics in so many ways...so for those I respect and keep posting some very intelligent information...kudos to you for helping us all stay informed.
Thanks Michele....its not my objective to appease you or anybody else here. And for someone who claims to hold millions upon millions of shares....your thoughts and feedback is as shallow as a adolescent swimming pool (you always say "Cashback Kaboom"...can you inform us exactly how that brilliant analysis translates into something meaningful). LMAO!
JP:
Thanks. I am a Realist; I continue to hold a rather substantial position and I have not sold any shares (I buy and invest in good companies who have stellar Mgt., solid drug technology and most importantly who can execute). We had some growing pains here; but I am thinking that there is too much S/T pressure for LymPro to succeed and be a HUGE success (and it just seems to me that our Non dilutive funding will come from other places ..that arent expected...pure speculation on my part...but thats why I am excited). Also, the recent share structure change reflecting Phenoguard as a separate division ....is something that tells me the financial re-engineering that Gerald speaks to will happen..just timing from here).
Btw; JP - you have done a magnificent job keeping all of us shareholders informed; and I admire your efforts and due diligence that you have communicated along the way. Objective analysis is very welcomed here..just wish others were capable and willing to see it how you do.
Thank you Sir!
Risk:
You have to love Wall Street ...all the market maker games to wash out the weak sellers. I have seen this one too many times; as I believe the latest shakeout is a precursor to the so called BIG ONE on the way (now, the Annual meeting is almost 10 days away too...I would be hopeful that Gerald and Mgt. are ready to make their move sometime within Q4.
Also, the Uplisting will happen on communicated time-frames (January 2015 at the latest); and I believe the long awaited Partnership that we are all looking for LymPro will happen elsewhere within the Pipeline....with like MANF, EltoPrazine or Phenoguard (these guys want the stock listed on Nasdaq as soon as possible (watch for the the surprise announcement to happen over the next month or two..or no later than December).
The NASDAQ will be the place to be....if you want to make money and get Institutional sponsorship and buying....strong business fundamentals and great Science will take care of the Shorts.
Thanks JP...just keeping it real. I appreciate all of your DD and sharing your thoughts as well.
We will prevail........
Eltoprazine Phase 2b Trial startup on the way. So much focus has been on LymPro; but if we can get this trial up and running (and more importantly, if we can get grant funding from like the Michael J. Fox foundation)and they provide initial funding...you will get your PPS double within days or a week of this announcement.
Also, I think the days of weeding through the Pre clinical news is slowly going to abate; as I am gearing up for more significant news that should help propel the PPS upward (as everyone has been waiting for). Moreover, as the sentiment here on this board has changed more bearish recently which is rather obvious based on the postings over the last week or two.....this is a bullish sign for me as the retail crowd rarely gets it right too.
Pre Market Monday news will gap us up; who knows if it will happen but I believe many or some will be caught off guard.
Dont over analyze the antics on Wall Street. The Whales will take every opportunity to make money on the way up and the way down (in between PR's).
Big accumulation going down here ahead of a string of significant PR's that are on the way.......when their is blood in the streets; its time to BUY!!!
My pleasure Risk...thanks for post and feedback. I am happy to be in good graces with the family members as well.
I believe this marks a significant turning point in our journey ....$.20 cents will be child's play in regards to what Gerald (and his team) have in store for us shareholders.
Enjoy the ride..........:)
Wow! I tend to be very objective in my analysis; but that is by far one of the most intriguing and impressive Blogs that Gerald has ever released.
Very concise, extremely detailed and a very well executed game-plan (on deck) which has been clearly articulated and outlined. I would say without hesitation; this PPS is grossly undervalued and should see in immediate increase based on upcoming events and catalysts that Gerald has communicated quite well.
Finally, tt is both a privilege and a pleasure to be a very large shareholder of this company and respective investment (and good luck flippers and shorts...you are about to be fried).
FYI:
"Jason Napodano, CFA ?@JNapodano 3m
@nomorefor @solantey The revenue opportunity for LymPro under CLIA is large but it will take 6+ months to get incorporated into protocols.
Jason Napodano, CFA ?@JNapodano 2m
@nomorefor @solantey But I would expect meaningful revenues once incorporated into the trial design. Very rapid ramp once initiated.
JP: I believe once Gerald connects all the dots with the interim LymPro results. We will be back above $.15 as early as Monday...and over $.20 within a week or two as further developments are announced.
What a privilege to load a huge position well below $.10. Its all about risk/reward with Bio's; proper due diligence a huge mustas well.
Outstanding 5 star post!!!
How funny that this simple clarification on the fact that the interim results were based use of one biomarker and that their are others that will be integrated shortly.... validates that LymPro is well in tact and following a gameplan...and a Partnership will come in due time.
Also, if many here just realize that the caliber of the hires alone will turn this company into a potential huge success. Look at the bigger picture.... their established relationships, network contacts, filed patents, posted Scientific journal articles and abstracts ..and experience working in top notch pharmaceutical companies...gives me enormous confidence that this really one day into the future....will really be....."EPIC".
Note: If someone claims that LymPro is an utter failure; ask for their Scientific credentials and license information (to substantiate how their qualified opinion matters). Let me guess...each person will be a no show with nothing to say. Speaks for itself.
How cool to see Amarantus invest in a new science and technology to help treat concussions. Whats most interesting is that that AMBS is building an empire one day at a time. They are planting the seeds to one day be the next Biotech powerhouse (very talented management team, advisory board, board of directors here). Could we possibly be an Amgen or Celgene? (YES!)
The just locked up P-16 Alzheimers technology with the German outfit and continue to quietly be a VERY diversified company with multiple product lines, technology, a MANF drug and the Phenoguard science (a pure incubator where the next MANF type drug could be spun out any day). If everyone would take some focus away from LymPro and just understand whats coming together; there is a reason why there were HUGE big buys coming back into the stock (as the smart money knows the true underlying value of this company).
We have a Long Term WINNER ....Btw: Cerora is based where I grew up; I would like to learn more about this initiative as it evolves. GLTA!!!!
Proprietary ‘Near the Field’ Objective Concussion Evaluation Technology
BETHLEHEM, PA / ACCESSWIRE / August 1, 2014 / Cerora, Inc., a StartUp Health /GE Healthcare Entrepreneurship program and Ben Franklin Technology Partners of Northeastern Pennsylvania company, today announced a second closing in its seed financing, bringing total funds raised in this round to just above $600,000. This funding will support the commercial launch of Qumpass(TM), the company’s first software product launching this month, and the further development of its Borealis(TM) hardware/software solution for delivering objective brainwave biosensor data to help evaluate concussions right ‘near the field’ of play and in schools for ‘Return-to-Learn’ decision making. Investors in the second closing include The Brewer Group, Inc, Amarantus Bioscience Holdings, Inc. and Marvin S. Cadwell, an experienced health service executive.
"Objective data, rapidly provided near the athletic field would empower field clinicians evaluating concussions with a considerable diagnostic advantage over current assessment techniques," said Adam J. Simon, President & CEO of Cerora. "By empowering field clinicians with objective real-time brain health information, as opposed to subjective clinical impressions, Cerora will improve health outcomes for patients. With these investor commitments to Cerora in hand, our development and commercialization plans can now shift into high gear."
Cerora’s Borealis(TM) multimodal biosensor technology is designed to enable professionals to gather truly objective diagnostic information, which, along with neuropsychological performance data, self-reporting of symptoms, and additional biosensor-based measures, may lead to more accurate determinations. The Company also intends to develop applications of its Borealis(TM) technology for neurodegenerative conditions (such as cognitive impairment and Alzheimer’s disease), developmental conditions (such as Autism), and other brain-affecting conditions where portable, rapid development of objective data can be critical to the early diagnoses that are key to improved patient outcomes.
About Cerora
Cerora is leading the way in the development and testing of the software and hardware technologies (including the Google Glass platform), that will be needed to deliver critically important, objective, portable biomarker-based brain-function diagnostic information to empower health care professionals’ decisions. Located in the high-tech nexus at Ben Franklin Technology Partners of Northeastern Pennsylvania’s TechVentures on Lehigh University’s Mountaintop Campus in Bethlehem, Pennsylvania, the company has assembled a team of experienced scientists and management professionals under the leadership of CEO Adam J. Simon, PhD, a noted physicist and globally-recognized brain biomarker expert.
I must admit this is the most fascinating board. So many bona fide experts all in one place. Amarantus is not a one trick pony; MANF is their flagship product and really what this company's future is all about.
Also, Eltoprazine has enormous potential and will be in a Phase 2b trial soon. Yes, it would be ideal to fund MANF trials internally; so I hope LymPro turns out to be a huge success (only time will tell; but anybody who has drawn any conclusion that it has failed is full of crap).
The LymPro data was only an interim look based a very small patient population. Do we know whether LymPro will succeed or fail? Absolutely not...the capability to tweak the sensitivity still exists to a much higher rate exists. See excerpt from today press release stated below:
"Our ability to fine tune the assay to optimize for sensitivity in an Alzheimer's cohort, while retaining acceptable specificity in the non-Alzheimer's cohort is extremely valuable. We are looking forward to completing enrollment in this trial and analyzing the full dataset?.
As always, please do your own due diligence as trusting anybody here is hazardous to your wealth building potential. Trust in you Mgt. team (and be patient; the one's who cry wolf are the ones who wanted to make an overnight fortune ...Wall Street is much smarter than most of you...but many dont see how the forces control the trading price to wear down the retail crowd).
Lastly, if you adjust your time horizon as to how you define success; you will then realize that the day to day trading price is irrelevant...the PPS is going significantly higher folks.
We shall see where the truth lies; but Gerald will be addressing Shareholders tomorrow (so stay tuned). Btw: I copied this from the Yahoo MB:
Conversation on twr
$AMBS congrats all. #LymPro V1 interim data (p=0.003) exceeded even my calculations. Take a bow, Dr. Thomas Arendt. Stay tuned for LymPro V2
Expand
Reply
Retweeted
Favorited
jbplens ?@jbplens 50m
@fibonacci1170 source of this information?
Expand
Reply
Retweet
Favorite
Retweeted by nj46nick
fibonacci ?@fibonacci1170 32m
@jbplens $AMBS presented univariate results w/o any stat modeling. Bridge study will compare Alz vs cognitively intact controls. Can top 95% Less
Sentiment: Strong Buy
Today: Brilliant Market Maker action today!!! Result: They flushed the stop loss orders through and scared the weak holders out as well. In my opinion, its very bullish action to witness what happened today.
Tomorrow: Management has every opportunity to showcase LymPro (and the company...so I am expecting a surprise here). Perhaps, we could get news about LymPro's ability to diagnose concussions more clearly or capability to diagnose other diseases in more depth = LymPro will be a Billion dollar product (thats my speculative theory).
In addition, if they have huge success in a small patient population; they can simply replicate those findings in a bigger patient populations (so a sampling might be all thats needed to validate that LymPro works extremely well....and that the medical community will both understand and recognize that reality.
Finally, there were some really HUGE buy orders flowing all day; the smart money knows where the PPS is going and built larger positions with today's action. Good Luck longs..as the Bulls are in charge!!!
Absolutely no gaps on the chart. Its a beautiful thing. Thanks Pistol Pete.
Well said!! Get ready for the US govt. to mint a new coin or currency with the following on it:
"In Gerald We Trust".
Now if we can just get people to focus on AMBS versus responding to baseless and fabricated feedback; we can clean this board up and focus on the AMBS fundamentals (and business plan execution).
I am more excited in AMBS (as an investment) than any other one that I have owned in the last 20 years. Know what you own; and do your own due diligence (for heavens sakes).
Thanks JP: I tend to be conservative and did the valuation on whats known today (but I understand that the potential upside to calculate fair value can change significantly overnight based on any fundamental change in the business plan).
AMBS has made some great strides; but I am so looking forward to when we start getting some very material news (and thats not too far away). The leaps forward will be more significant for the stock price; and the smart money knows this and is clearly accumulating (as you have articulated many times over... watch and learn for those who are skeptical or don't believe in the company's science or its plan).
Finally, the old adage on Wall street; "Climb the wall of worry"...LymPro will have unbelievable success and AMBS will have its own stage and focus on 7/31 (which is exactly what Gerald and his management team want exactly).
Risk: In the essence of time; I will simply piggyback on Jason Napadano's analyst report back from May, 2013. At that time, he projected LymPro CLIA approval in early 2015.
Whats most interesting is he valued LymPro Revenue as follows:
2015 at $2mm
2016 at $22mm
2017 at $57mm
2018 at $128mm.
Most importantly, I like his conservative estimating; but I expect the numbers will be more robust. The legwork that Gerald (and his team has invested with working with KOL's) will significantly improve the valuation early on):
My LymPro revenue projections:
2015 at $30mm
2016 at $60mm
2017 at $100mm
2018 at $240mm
I just think the ramp up to major success will take time (until they receive full blown FDA approval) in 2018.
In terms of valuation, It appears Jason N. calculated a Diagnostics division - Net Present Value at $40mm back in May 2013 and I think he will be correct in that prediction; there are always hold ups or delays that come along. So if he valued the Diagnostic division at $40mm for $128mm in project revenues in 2018 (my guess is the Diagnostic division would be worth $84mm today based on a $240mm Revenues in 2018).
In addition, he valued MANF at $77mm at that time (alot has changed). Specifically, he said any Orphan indications would add massive upside to his valuation. MANF is worth more today; my guess is $130mm in valuation. Moreover, they have added Eltoprazine which has added another $75mm (my guess).
Overall, there are so many moving parts and future unknowns as things move forward:
1) Patents
2) License fees
3) Partnerships
4) Non dilutive funding
Combined Valuation(my projection) is as follows:
1) Diagnostics division = $84mm
2) MANF = $130mm
3) Eltoprazine = $75mm (because its already in a Phase 2b)
4) Other = $30mm (Nuropro, patents, intellectual property, etc.)
TOTAL PROJECTED VALUATION = $319mm
Current stock price @ $.1345 = $99.1mm
My Analysis equates to a true estimated market cap.of $319mm which translates into a stock price of around $.42-46 today.
Cheers!
Special note: Amyvid sold for 20x Revenues (Lilly received $300 million upfront and $500 million in the backend). This valuation was right around the estimated $750 million peak market opportunity.
If LymPro was at any major risk; the stock price would have broken way down by now. However, as soon as investors start to see major progress in MANF; it will begin to steal the show.
Most importantly, LymPro will be a funding vehicle for MANF (I do predict the Diagnostics division will be spun or sold off to fund MANF trials in many indications too). Believe in LymPro; but I would keep expectations reasonable to how much Revenue will be booked in the early going.
Its an incredible (and well diversified company)...once in a lifetime investment here.
At some point the doubters and haters will soon recognize that the chart doesn't lie. We are going significantly higher folks; please LISTEN to management and disregard anybody who is desperately trying to discredit management (and its intentions) in any way.
MANY + LYMPRO = $$$$ ...I am a believer!!
A successful company or investment doesnt have to prove itself overnight or based on your timing and expectations. There are a number of factors that can delay progress or release of information that you arent aware of either. Maybe the future LymPro partner has its own requirements and expectations that Gerald must follow as a precursor to doing a respective partnership deal.
Btw: The Longs have done their due diligence and dont need anybody preaching to the choir (for some reason; you have an axe to grind here one way or another).